Oncology trials in a shifting economical and geopolitical landscape

Webinar: Oncology trials in a shifting economical and geopolitical landscape

The pharmaceutical and biotech fields are spinning around, seeking to adapt to the current geopolitical situation and its impact on current and future oncology trials. Many trials have been shifted to other countries or regions while the complexity of managing risk increases.

Even though managing your studies in these economic times might seem challenging, all you need is thoughtful preparation and adaptation measures. Our experts will share practical tips and experience-based results on how you can do it too.

Planning your next oncology study?

Let’s talk how we can team up to conduct them effectively and ensure smooth processes.

What we will talk about?

Our experts will:

1. Give practical advice on how to plan your clinical study budget effectively;
2. Share the experience of successful geography shifts for ongoing clinical studies;
3. Discuss global tendencies in oncology clinical trials and how to adapt to them;
4. Talk about how to handle risk management.

    Duration: 50 minutes.

    Speakers:

    • Regina Auškalnienė, Chief Global Clinical Research Officer
    • Vladimir Mukovozchik, Head of Project Management
    • Oleg Kungurtsev, Head of Clinical Monitoring
    Regina Auškalnienė

    Regina Auškalnienė

    Chief Global Clinical Research Officer

    Other content that might interest you:

    No Results Found

    The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

    Running a clinical trial in the Baltic states

    Running a clinical trial in the Baltic states

    In the past five years, an average of 175 clinical trials are being initiated in the Baltic states each year. An average of 64,8% of the population in the Baltic states are in the age from 15 to 65 years old, the main target audience for clinical trials. Furthermore, a large pool of treatment-naïve subjects is available compared to other EU countries or the US. Patients with special therapeutic diseases are transferred to the main central hospitals.

    read more
    Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

    Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

    On 29th March 2017 UK submitted the notification of its intention to withdraw from the EU. This means that UK will become a ‘third country’ from 30th March’19. Even though leaving the EU with a deal remains the Government’s top priority, UK drug agency is publishing a series of guidance documents for industry and other stakeholders covering the proposed arrangements for the regulation of medicines, medical devices and clinical trials, if UK leaves EU with no deal.

    read more
    Tuberculosis Medicines Clinical Development in Eastern Europe and CIS

    Tuberculosis Medicines Clinical Development in Eastern Europe and CIS

    World Tuberculosis Day is commemorated every year on 24th March to raise awareness of tuberculosis, which is still causing death of nearly 1.5 million people each year, mostly in developing countries. It marks the day in 1882, when Dr. Robert Koch announced that he had discovered the cause of tuberculosis, the TB bacillus. In comparison to other infectious diseases caused by a single infectious agent, tuberculosis is the second biggest killer worldwide.

    read more

    Big Enough To Cover  All Your Needs. Small Enough To Care.

    Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

    Clinical Research

    Regulatory Affairs

    Pharmacovigilance

    Medical Information